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ABSTRACT 
 
Objectives: This is a retrospective crossectional study designated to describe 
the histopathological patterns of endometrial biopsies in postmenopausal 
bleeding (PMB) and to estimate the risk of endometrial cancer in endometrial 
biopsies taken from women presenting with PMB. 
Materials and Methods: The study included 146 endometrial biopsies taken 
from women presenting with PMB at National Health Laboratory during the 
period from January 2009-June 2010.Data on procedure of endometrial 
sampling and pathological findings were obtained from files of the National 
Health Laboratory on predesigned questionnaire, slides, blocks and 
histopathology reports were revised by the investigator and supervisor 
.Results obtained were analysed using SSPS soft ware. 
Results: The procedure of endometrial sampling was dilatation and curettage 
in 95 (65.06%) of biopsies, hysterectomy in 46 (31.50%) and polypectomy in 
5( 3.44% )of patients.   
Benign lesions constituted 71.9% with endometrial polyps being the most 
frequent pattern (19.9%). Malignant lesions were diagnosed in 15.8% of 
biopsies, while 12.3% of endometrial biopsies were inadequate for 
interpretation.  
Endometrial hyperplasia without atypia was found in 17.8% of endometrial 
biopsies; of which 84.62% were simple hyperplasia and 15.38% were 
complex hyperplasia. Endometrial cancer was diagnosed in 15.8% of 
endometrial biopsies with endometrioid adenocarcinoma being the most 
common histolopathological type (73.9%), 41.2% were poorly differentiated 
adenocarcinoma. Other patterns included proliferative endometrium, atrophic 
 endometrium, and chronic endometritis were present in 11%, 7.5% and 4.8% 
respectively.  
Conclusion: The majority of histopathological findings in PMB were benign 
lesions (71.9%).Among the benign lesions endometrial polyps were the most 
predominant pattern. The malignancy risk of endometrial cancer was found to 
be 15.8%. 
 
 
 
 
 
 
 
 
 
                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  ﻣﺴﺘﺨﻠﺺ
 
ﺍﻻﻨﺴﺠﻪ ﻓﻰ  ﻫﺫﻩ ﺩﺭﺍﺴﻪ ﻗﻬﻘﺭﻴﻪ ﻤﻘﻁﻌﻴﻪ ﺼﻤﻤﺕ ﻟﻠﺘﻌﺭﻑ ﻏﻠﻰ ﺍﻟﺘﻐﻴﺭﺍﺕ ﺍﻟﻤﺭﻀﻴﻪ ﻓﻰ:ﺍﻻﻫﺩﺍﻑ 
 ﺍﻟﺭﺤﻡ ﻓﻰ ﻨﺯﻑ ﻤﺎ ﺒﻌﺩ ﺍﻻﻴﺎﺱ ﻭﺘﻘﺩﻴﺭ  ﺨﻁﺭ ﺴﺭﻁﺎﻥ ﺒﻁﺎﻨﺔ ﺍﻟﺭﺤﻡ ﻓﻲ ﺍﻟﻌﻴﻨﺎﺕﺍﻟﻌﻴﻨﺎﺕ ﻤﻥ ﺒﻁﺎﻨﻪ 
  .ﺍﻟﻤﺎﺨﻭﺩﺓ ﻤﻥ ﺒﻁﺎﻨﺔ ﺍﻟﺭﺤﻡ ﻤﻥ ﺍﻟﻨﺴﺎﺀ ﺍﻟﻼﺘﻲ ﺍﺘﻴﻥ ﺒﻨﺯﻑ  ﻤﺎﺒﻌﺩ ﺍﻻﻴﺎﺱ
ﻋﻴﻨﻪ ﻤﻥ ﺒﻁﺎﻨﻪ ﺍﻟﺭﺤﻡ ﺍﺨﺫﺕ ﻤﻥ ﺍﻟﻨﺴﺎﺀ ﺍﻟﻼﺘﻰ  41 6ﺍﺸﺘﻤﻠﺕ ﺍﻟﺩﺭﺍﺴﻪ ﻋﻠﻰ: ﻤﻨﻬﺠﻴﺔ ﺍﻟﺒﺤﺙ
ﻭﺤﺘﻰ ﻡ 9002ﺼﺤﻰ ﺨﻼل ﺍﻟﻔﺘﺭﺓ ﻤﺎ ﺒﻴﻥ ﻴﻨﺎﻴﺭ  ﺍﺘﻴﻥ ﺒﻨﺯﻑ ﻤﺎ ﺒﻌﺩﺍﻹﻴﺎﺱ ﺒﺎﻟﻤﻌﻤـل ﺍﻟﻘﻭﻤﻰ   ﺍﻟ
ﺍﻟﻤﻌﻠﻭﻤﺎﺕ ﻋﻥ ﻭﺴﻴﻠﻪ ﺍﺨﺫ ﺍﻟﻌﻴﻨﻪ ﻤﻥ ﺒﻁﺎﻨﻪ ﺍﻟﺭﺤﻡ ﻭﺍﻟﻨﺘﺎﺌﺞ  ﻋﻠﻰ  ﺘﻡ ﺍﻟﺤﺼﻭل. ﻡ0102ﻴﻭﻨﻴﻭ 
ﻭﻤﻥ ﺜﻡ ﺘﻤﺕ . ﻤﻠﻔﺎﺕ ﺍﻟﻤﺭﻀﻲ ﺒﺎﻟﻤﻌﻤل ﺍﻟﻘﻭﻤﻰ ﺍﻟﺼﺤﻰ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺍﺴﺘﺒﻴﺎﻥ ﻤﻌﺩ ﻤﺴﺒﻘﺎﹰ ﺍﻟﻤﺭﻀﻴﻪ  ﻤﻥ
 ﻭﻤﻥ ﺜﻡ ﺤﻠﻠﺕ. ﺍﻟﺸﺭﺍﺌﺢ، ﺍﻟﻤﻘﺎﻁﻊ، ﻭﺘﻘﺎﺭﻴﺭ ﺍﻷﻨﺴﺠﺔ ﺍﻟﻤﺭﻴﻀﺔ ﺒﻭﺍﺴﻁﺔ ﺍﻟﺒﺎﺤﺙ ﻭﺍﻟﻤﺸﺭﻑ  ﻤﺭﺍﺠﻌﺔ
  . SPSS    ﺍﻟﻨﺘﺎﺌﺞ ﺇﺤﺼﺎﺌﻴﺎ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺒﺭﻨﺎﻤﺞ ﺍﻟﺤﺎﺴﻭﺏ
 59 ﻓﻲ ﺕﺤﻜﺘﻡ ﺍﻟﺤﺼﻭل ﻋﻠﻰ ﺍﻟﻌﻴﻨﺎﺕ ﻤﻥ ﺒﻁﺎﻨﻪ ﺍﻟﺭﺤﻡ ﺒﻭﺍﺴﻁﻪ ﺍﻟﺘﻭﺴﻴﻊ ﻭﺍﻟ: ﺍﻟﻨﺘﺎﺌﺞ
 5ﻭﺍﺴﺘﺌﺼﺎل ﺍﻟﺴﻠﻴﻠﻪ ﻓﻰ  (% 5.130)  64ﺍﻟﻌﻴﻨﺎﺕ ﻭﻋﻥ ﻁﺭﻴﻕ ﺍﺯﺍﻟﻪ ﺍﻟﺭﺤﻡ ﻓﻲ   ﻤﻥ %( 60.56)
ﺍﻟﺭﺤﻡ  ﺴﻠﻴﻼﺕ ﺒﻁﺎﻨﻪ  ﻭﻜﺎﻨﺕ% 9.17 ﺸﻜﻠﺕ ﺍﻻﻓﺎﺕ ﺍﻟﺤﻤﻴﺩﻩ ﻨﺴﺒﻪ  .ﻤﻥ ﺍﻟﻤﺭﻀﻰ%( 44.4)
ﻏﻴﺭ ﻜﺎﻓﻴﺔ  ﺕﻜﺎﻨ ﺕﻤﻥ ﺍﻟﻌﻴﻨﺎ %3.21، %8.51ﺍﻻﻭﺭﺍﻡ ﺍﻟﺨﺒﻴﺜﻪ  ﺒﻴﻨﻤﺎ ﺸﻜﻠﺕ% 9.91ﻜﺭﺍﺭﺍ ﺘ ﺍﻜﺜﺭﻫﺎ
 ﻤﻨﻬﻡ %26.48ﺍﻟﻌﻴﻨﺎﺕﻤﻥ %  8.71ﻭﺠﺩ ﻓﺭﻁ ﺍﻟﺘﻨﺴﺞ ﺍﻟﻐﻴﺭ ﻻﻨﻤﻁﻲ ﻓﻰ ﺒﻁﺎﻨﻪ ﺍﻟﺭﺤﻡ ﻓﻰ  .ﻔﺴﻴﺭﺘﻟﻠ
  ﺍﻟﺭﺤﻡ ﻓﻰ ﺘﻡ  ﺘﺸﺨﻴﺹ ﺴﺭﻁﺎﻥ ﺒﻁﺎﻨﻪ. ﻫﻰ ﻓﺭﻁ ﺘﻨﺴﺞ ﻤﺭﻜﺏ%  83.51ﻓﺭﻁ ﺘﻨﺴﺞ ﺒﺴﻴﻁ ﻭ  ﻫﻰ
ﻭﺍﻉ ﺍﻟﻨﺴﻴﺠﻴﻪ ﺍﻻﻨ ﻭﻜﺎﻥ ﺍﻟﻭﺭﻡ ﺍﻟﺒﻁﺎﻨﺎﻨﻰ ﺍﻟﺭﺤﻤﻰ ﺍﻟﻐﺩﻯ ﺍﻟﺴﺭﻁﺎﻨﻰ ﺍﻜﺜﺭ. ﻤﻥ ﺍﻟﻌﻴﻨﺎﺕ %  8.51
ﺍﻟﺭﺤﻡ ﺒﻁﺎﻨﻪ ﻭﺭﺍﻡ ﻏﺩﻴﻪ ﺴﺭﻁﺎﻨﻴﻪ ﻀﻌﻴﻔﻪ ﺍﻟﺘﻔﺎﻀل، ﻤﻨﻬﻡ ﻫﻰ ﺍ%  2.14 ،% 9.37ﺸﻴﻭﻋﺎ ﺒﻨﺴﺒﻪ 
 ﻭ  % 5.7ﻭ%  11ﻭﺠﺩﺕ ﺒﻨﺴﺒﻪ  ﺒﻁﺎﻨﺔ ﺍﻟﺭﺤﻡ ﺍﻟﻀﻤﻭﺭﻱ ﻭﺍﻟﺘﻬﺎﺏ ﺒﻁﺎﻨﻪ ﺍﻟﺭﺤﻡ ﺍﻟﻤﺯﻤﻥﻭﺍﻟﺘﻜﺎﺜﺭﻯ 
 . ﻋﻠﻰ ﺍﻟﺘﻭﺍﻟﻰ % 8.4
ﻏﺎﻟﺒﻴﻪ ﺍﻟﺘﻐﻴﺭﺍﺕ ﺍﻟﻤﺭﻀﻴﻪ ﻓﻰ ﺍﻻﻨﺴﺠﻪ ﻓﻰ ﻨﺯﻑ ﻤﺎ ﺒﻌﺩ ﺍﻻﻴﺎﺱ ﻫﻰ ﺍﻓﺎﺕ ﺤﻤﻴﺩﻩ  :ﺍﻟﺘﻀﻤﻴﻥ
ﺎﻥ ﺒﻁﺎﻨﻪ ﺍﻟﺭﺤﻡ ﺴﻠﻴﻼﺕ ﺒﻁﺎﻨﻪ ﺍﻟﺭﺤﻡ ﻫﻰ ﺍﻜﺜﺭ ﺍﻻﻨﻭﺍﻉ ﺍﻟﻨﺴﺠﻴﻪ ﺴﻴﺎﺩﻩ ﻭﻨﺴﺒﻪ ﺨﻁﺭ ﺴﺭﻁ%. 9.17
  %. 8.51ﻨﺯﻑ ﻤﺎ ﺒﻌﺩ ﺍﻻﻴﺎﺱ ﻫﻰ   ﻓﻲ
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INTRODUCTION AND LITERATURE REVIEW  
 
Introduction to menopause: 
Menopause is a universal and irreversible part of the overall aging 
process involving a woman's reproductive system, after which she no 
longer menstruates. Climacteric is the general term for the time from the 
period of this transition to the early postmenopausal phase of a woman's 
reproductive life cycle.(1)  
 Epidemiology:  
The increasing number of middle-aged and older individuals 
includes a concomitant and continuing rise in the number of women who 
live most of their lives in a hypoestrogenic state. More and more women 
can expect to live approximately 79 years and to experience the 
consequences of gonadal hormone loss. The actual age of menopause, 
approximately 50-51 years, with the symptomatic transition to menopause 
usually commencing at approximately age 45.5 - 47.5 years.(1,2) Factors that 
lower the age of physiologic menopause include smoking,(2) hysterectomy, 
Fragile X carrier, autoimmune disorders, living at high altitude, or history 
of certain chemotherapy medications and/or radiation treatment. 
Physiology of menopause: 
Menopause results from loss of ovarian sensitivity to gonadotropin 
stimulation, which is directly related to follicular decline and dysfunction. 
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The oocytes in the ovaries undergo atresia throughout a woman's life cycle, 
and both the quantity and quality of follicles undergo a critical decline 
approximately 20-25 years after menarche. Thus, the variable menstrual 
cycle length during perimenopause can be due to anovulation or to irregular 
maturation of follicles. A shorter menstrual cycle length is the most 
common change that occurs during the perimenopausal period in women 
who have no pelvic pathology and who continue to ovulate.(3) The follicular 
phase of the menstrual cycle shortens because of the decreased number of 
functional follicles. Because these follicles, which are stimulated by 
follicle-stimulating hormone (FSH) during the first part of the menstrual 
cycle, have declined in number, less recruitment of oocytes occurs and the 
follicular phase shortens accordingly. Over time, as aging follicles become 
more resistant to gonadotropin stimulation, circulating FSH and luteinizing 
hormone (LH) levels increase. Elevated FSH and LH levels lead to stromal 
stimulation of the ovary, with a resultant increase in estrone levels and a 
decrease in estradiol levels. Inhibin levels also drop during this time 
because of the negative feedback of elevated FSH levels.(4) With the 
commencement of menopause and a loss of functioning follicles, the most 
significant change in the hormonal profile is the dramatic decrease in 
circulating estrogen levels. Without a follicular source, the larger 
proportion of postmenopausal estrogen is derived from ovarian stromal and 
adrenal secretion of androstenedione, which is aromatized to estrone in the 
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peripheral circulation.(5) With cessation of ovulation, estrogen production 
by the aromatization of androgens in the ovarian stroma and production in 
extragonadal sites continue, unopposed by progesterone production by a 
corpus luteum. Perimenopausal and menopausal women are thus often 
exposed to unopposed estrogen for long periods, which can lead to 
endometrial hyperplasia, a precursor of endometrial cancer. Estradiol levels 
decrease significantly because of loss of follicular production with 
menopause and postmenopause, but estrone, which is aromatized from 
androstenedione from nonfollicular sources, is still produced and is the 
major source of circulating estrogen in the postmenopausal female.(1) The 
clinical indication that menopause has occurred is the measure of an 
elevated FSH level. The FSH level rises more than the LH level because of 
the reduced renal clearance of FSH compared with LH. A slightly elevated 
or borderline menopausal FSH level in a perimenopausal woman may not 
be a reliable indicator of menopause because of the wide variation of FSH 
and LH levels in response to increased release of gonadotropin-releasing 
hormone (GnRH) by the hypothalamus and increased pituitary sensitivity 
to GnRH. Measuring FSH and LH levels again in the perimenopausal 
patient after 2-3 months is helpful in establishing whether the woman is 
progressing through menopause.(1) 
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Clinical effects of menopause: 
Throughout the time when the physiologic changes in responsiveness 
to gonadotropins and their secretions occur, with resultant wide variation in 
hormonal levels, women often experience several symptoms that are 
collectively termed the climacteric syndrome. Typical climacteric 
symptoms include hot flashes or flushes, insomnia, weight gain, mood 
changes, irregular menses, and headache. As already noted, the length of 
time over which the climacteric occurs is widely variable; symptoms may 
begin during perimenopause and continue for 5-10 years after menopause. 
Irregular ovarian function and considerable estrogen level fluctuation not a 
deficiency of estrogen cause climacteric symptoms during menopause 
.Cessation of menstruation in women of the appropriate age continues to be 
the best confirmation of loss of follicular function as post menopause years 
progress with an accompanying loss of ovarian response to gonadotrophins. 
Associated symptoms of the climacteric also decline.(1) 
The effects of gonadal hormone depletion can be obvious on pelvic 
examination. With loss of estrogen, the vaginal epithelium becomes redder 
because of thinning of the epithelial layer and increased visibility of the 
small capillaries below the surface. Later, as the vaginal epithelium further 
atrophies, the surface becomes pale because of a reduced number of 
capillaries. Rugation also diminishes, and the vaginal wall becomes 
smooth. Inside the pelvis, the uterus becomes smaller. Fibroids, if present, 
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become less symptomatic. Endometriosis and adenomyosis are also 
alleviated with the onset of menopause, and many patients with pelvic pain 
finally achieve permanent pain relief. 
The menopausal ovary diminishes in size and is no longer palpable 
during gynecologic examination. A palpable ovary on pelvic examination 
warrants a full evaluation in all women who are menopausal or 
postmenopausal.(5) 
Osteoporosis and menopause: 
With the onset of menopause, BMD is rapidly lost because bone 
resorption, uncoupled with bone formation, is accelerated, where as 
formation continues at the premenopausal rate. Trabecular bone is affected 
more than cortical bone, and bone loss is therefore more commonly 
observed at vertebral and radial sites. Normal bone loss associated with 
senescence is different from the accelerated bone loss observed after 
menopause. Bone loss in the few years after onset of menopause may be as 
high as 20% of lifetime bone loss. Osteoclasts have been shown to have 
estrogen receptors, and these are hypothesized to be the mechanism by 
which estrogen replacement protects against osteoporosis.(5)Estrogen 
therapy (ET) is still considered a good therapy for osteoporosis, 
Postmenopausal women and elderly women should be treated early and on 
a long-term basis unless estrogen therapy is contraindicated.(6)  
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Cardiovascular issues and menopause: 
Coronary artery disease (CAD) is the leading cause of morbidity and 
mortality in men and postmenopausal women. Menopause increases the 
risk for women still further, independent of age. Prior to menopause, the 
risk of CAD for women lags behind the risk for men by approximately 10 
years. After menopause, women come to have similar risks of CAD as men 
of the same age.(7) Initiating hormone therapy or estrogen therapy in the 
immediate peri or postmenopausal time is believed to be beneficial because 
significant atherosclerotic changes have not yet occurred. The benefit of 
estrogen on cardiovascular mortality rates is due to many factors. One 
mechanism appears to be estrogen effects on lipid metabolism, which 
includes reducing low-density lipoprotein (LDL) and increasing high 
density lipoprotein (HDL).(8)  
Breast cancer and menopause: 
Estrogen therapy is known to benefit postmenopausal women in a 
multitude of ways, mostly through the relief of vasomotor symptoms 
associated with the postmenopausal time. Estrogen is also beneficial for the 
prevention and treatment of osteoporosis. Much controversy exists about 
the use of estrogen and breast cancer. Some studies show an increased risk 
of breast cancer with postmenopausal estrogen use, whereas others show a 
decrease. Estrogen's possible link to cancer is also suggested by the fact 
that the risk of breast cancer is increased in women with an earlier age at 
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menarche and a later age at menopause. Currently, no woman with a strong 
family or personal history of breast cancer should be given hormone 
therapy or estrogen therapy.(9)   The risk appears to be related to duration of 
use, with longer-term users being more affected. Women with a history of 
using hormone therapy have more localized tumors as well as better 
survival rates. That is, women receiving hormone therapy who are 
diagnosed with breast cancer are found to have more favorable staging at 
the time of diagnosis , including smaller tumor size, negative lymph node 
involvement, and well-differentiated tumor histology.(10)  
Central nervous system and menopause: 
The association of estrogen and memory function is an intriguing 
area of research. Normal aging itself induces a decline in certain cognitive 
capabilities, and a lack of estrogen may contribute to this process. The 
estrogen effect is one of slowing the decline of preserved memory 
function.(11)  
Menopause markers: 
Gonadotropin secretion increases dramatically after menopause. FSH 
levels are higher than LH levels, and both rise to even higher levels than in 
the surge during the menstrual cycle. The FSH rise precedes that of LH. 
Endometrial biopsy can show a range of histological appearances, from 
mildly proliferate to atrophic. No secretory changes are observed after 
menopause because no ovulation occurs, and therefore, no corpus luteum 
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forms to produce progesterone. Endometrial hyperplasia is a sign of 
hyperstimulation by estrogen from either endogenous sources or 
replacement therapy and may be a precursor of endometrial cancer.(1,3)  
Replacement therapy and menopause: 
The main reasons to treat symptoms of estrogen level fluctuation 
prior to actual menopause are to provide relief of vasomotor symptoms, 
avoid irregularity of menstrual cycle and preserve bone. 
The time to begin therapy depends on the patient's current illness or 
illnesses, if any, and medical history. Whether a woman is perimenopausal 
or postmenopausal helps in choosing the most suitable type of therapy.  
Contraindications to estrogen therapy are undiagnosed vaginal 
bleeding, severe liver disease, venous thrombosis, and personal history of 
breast cancer.(11)  
Definition: 
Post menopausal bleeding: abnormal uterine bleeding that occurs at 
least one year after menopause has been established.(12)  
 Causes of abnormal uterine bleeding in postmenopausal years:  
1. Atrophy 25%. 
2. Organic lesion: hyperplasia 16%. 
3. Endometrial polyp 2-24%. 
4. Endometrial carcinoma10%. 
5. Exogenous hormones: 
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a. Oestrogen replacement. 
b. Progestin therapy e.g. therapy of breast cancer. 
6. Uncommon causes: 
a. Endometritis. 
b. Clotting disorders.  
Investigation of PMB: 
• History including duration and severity of bleeding, initiating 
factors such as intercourse or trauma. 
• History of risk factor for hyperplasia and adenocarinoma 
including anovulation, obesity, hypertension and diabetes.(12) 
• Medication HRT, topical estrogen,tamoxifen. 
• PAP smear. 
• Family history of gynecological cancer. 
• Gynecological history. 
• Obstetric history. 
Clinical examination:  
Abdominal, bimanual examination, speculum examination of the 
vagina and cervix. The clinical-gynecological investigation should prove 
the source of postmenopausal bleeding according to the anatomical site-
uterine, infra-, or suprauterine. The causes of infrauterine bleeding may 
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easily be diagnosed by means of inspection of the external genitalia and 
further by using a speculum. 
 Cytology and colposcopy: 
Cytology and colposcopy supported by bimanual examination, 
exclude cervical carcinoma as a cause of bleeding. Both adnexa should 
always be investigated and the findings sonographically documented, so 
that solid cystic masses in the adnexal area can be better identified as 
suprauterine causes of postmenopausal bleeding. Then the uterus should be 
investigated. The causes of uterine bleeding are of major importance. 
Atypical endometrial cells on the cytological smear arouse suspicion of 
endometrial carcinoma.(13) 
Transvaginal sonography (TVS):  
TVS is used as a first step in the diagnostic workup and is preferred 
over uniform biopsy of postmenopausal women with vaginal bleeding as 
(1) it is a less invasive procedure than endometrial biopsy, (2) is generally 
painless, (3) has no complications, and (4) may be more sensitive for 
detecting carcinoma than blind biopsy. A limitation of ultrasound is that an 
abnormal finding is not specific: ultrasound cannot always reliably 
distinguish between benign proliferation, hyperplasia, polyps, and 
cancer.(13)    
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Hydroultrasonography (Transvaginal ultrasound with SIS):  
 This is accomplished by placing a small volume of saline into the 
endometrial cavity and then repeating the vaginal ultrasonogram. 
In many instances in which the original vaginal ultrasonogram shows 
significant endometrial thickness, an ultrasonogram can help differentiate 
other pathology from true endometrial thickness. 
 Hysteroscopy is necessary in postmenopausal women with an 
endometrium of 4 mm or more, as well as in premenopausal patients with 
endometrial thickness more than 5 mm and in those with suspected polyps 
or myomas. In postmenopausal women without vaginal bleeding, the risk 
of cancer is approximately 6.7% if the endometrium is thick (> 11 mm) and 
0.002% if the endometrium is thin (< or = 11 mm).(14) 
Endometrial biopsy: 
Indication for endometrial biopsy or curettage: 
1. Determination of the cause of the abnormal uterine bleeding 
2. Assessment of the response of the endometrium to hormonal therapy 
especially estrogen replacement in perimenopausal and 
postmenopausal women. 
3. Evaluation the status of the endometrium in infertile patients including 
histologic dating 
4. Evacuation of products of conception.(15) 
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5.  Presence of atypical or abnormal glandular cells in a cervical-vaginal 
cytologic sample that requires endometrial sampling to exclude 
hyperplasia or carcinoma.(12)  
6.  Endometrial sampling prior to hysterectomy to exclude significant 
pathology, although this procedure yields little pathology in the 
absence of history of abnormal uterine bleeding.(16) 
Procedure: 
Although fractional dilatation and curettage was historically the 
definitive diagnostic procedure to help rule out endometrial cancer, in 
current practice endometrial biopsy as an office procedure is quick, well 
tolerated, and quite sensitive for making the diagnosis. 
If endometrial pathology is not present on biopsy specimens and the 
patient has no further bleeding, no additional diagnostic tests need to be 
performed. If the patient continues to be symptomatic, then further 
evaluation of the endometrial cavity is necessary. 
Hysteroscopically directed biopsy: Another diagnostic procedure 
that has been advocated by some as an even more accurate way of 
determining the status of the endometrium. 
Dilatation and curettage: The current role of the formal dilatation 
and curettage is probably very limited because the diagnosis can usually be 
made in the office. 
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Endometrial hyperplasia is a non physiologic non invasive 
proliferation of the endometrium that results in morphologic patterns of 
glands with irregular shapes and varying size. This disorder results from 
sustained un opposed oestrogen stimulation and presents clinically as 
abnormal uterine bleeding. Hyperplasia occurs most frequently in 
perimenopausal women since they frequently have anovulatory cycle, but 
also occurs in postmenopausal women who either have excess endogenous 
oestrogen level or are receiving exogenous oestrogen (18).Hyperplasia may 
arise on occasion in young women including teen agers, since sporadic 
anovulation occurs in the reproductive ages and anovulatory cycles are 
frequent in adolescents.(19) 
 World Health Organization (WHO) classification of endometrial 
hyperplasia: 
 This system characterizes the glandular architectural pattern as 
simple or complex and describes the presence or absence of nuclear atypia. 
Hyperplasia (without atypia): 
a. Simple hyperplasia: Increased number of glands but regular glandular 
architecture. 
b. Complex hyperplasia - Crowded irregular glands. 
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2. Atypical hyperplasia: 
a. Simple hyperplasia with atypia: Simple hyperplasia with presence 
of cytologic atypia (prominent nucleoli and nuclear 
pleomorphism) 
b. Complex hyperplasia with atypia: Complex hyperplasia with 
cytologic atypia. 
Simple hyperplasia was associated with a 1% rate of progression to 
cancer, 3% rate of progression to complex hyperplasia, and 8% rate of 
progression to simple atypical hyperplasia, whereas complex atypical 
hyperplasia had a 29% rate of progression to cancer.(20)  
Not only does the concern exist for atypical hyperplasia progressing 
to invasive cancer, but numerous studies found concurrent carcinoma at 
rates ranging from 17-52%.(21) Part of the difficulty in diagnosing 
concurrent carcinoma is due to lack of reproducibility in diagnosing 
hyperplasia, especially atypical hyperplasia versus carcinoma among even 
expert gynecologic pathologists.(22)   
Pathophysiology: 
Endometrial hyperplasia results from continuous estrogen 
stimulation that is unopposed by progesterone. This can be due to 
endogenous estrogen or exogenous estrogenic sources. Endogenous 
estrogen may be caused by chronic anovulation associated with polycystic 
ovary syndrome (PCOS) or perimenopause. Obesity also contributes to 
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unopposed estrogen exposure due to chronic high levels of estradiol that 
result from aromatization of androgens in adipose tissue and conversion of 
androstenedione to estrone. Endometrial hyperplasia and cancer can also 
result from estradiol-secreting ovarian tumors such as granulosa cell 
tumors.(20) 
Exogenous estrogen without progesterone has been associated with 
increased endometrial hyperplasia and adenocarcinoma. The 
Postmenopausal Estrogen/Progestin Interventions(PEPI) trial found that 
unopposed estrogen exposure with 0.625 mg of conjugated equine 
estrogens increased the risk of complex hyperplasia by 22.7% and atypical 
hyperplasia by 11.8% over 3 years of use compared with a less than 1% 
increase in placebo controls(24).   Tamoxifen, with its estrogenic effect on 
the endometrium, increases the risk of endometrial hyperplasia and 
endometrial cancer. The risk of progression to cancer is associated with an 
increased duration of use(25). 
The exact mechanism of estrogen's role in the transformation of 
normal endometrium to hyperplasia and cancer is unknown. Genetic 
alterations are known to be associated with hyperplasia and type I 
endometrial cancers. Lesions with hyperplasia are associated with 
microsatellite instability and defects in DNA mismatch repair genes. PTEN 
tumor suppressor gene mutations have also been found in 55% of 
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hyperplasia cases and 83% of hyperplasia cases once it has progressed to 
endometrial cancer.(26)  
Mortality/Morbidity: 
Endometrial carcinoma is the most common gynecologic malignancy 
and the fourth most common cancer in women,  significant morbidity or 
mortality can occur if endometrial hyperplasia is untreated or concurrent 
malignancy is present.  
Endometrial hyperplasia is often associated with irregular or heavy 
vaginal bleeding, which can lead to disruptions with quality of life. 
Occasionally, uterine hemorrhage occurs, which may necessitate medical 
or surgical interventions, and blood transfusion therapy. 
Age: 
Endometrial hyperplasia is most frequently diagnosed in 
postmenopausal women, but women of any age can be at risk if they are 
exposed to a source of unopposed estrogen. Endometrial hyperplasia can 
frequently be seen in young women with chronic anovulation. 
Clinical features: 
Other risk factors for endometrial hyperplasia are the same as 
those for endometrial adenocarcinoma, including obesity, nulliparity, early 
menarche, and late menopause. While unopposed estrogen in oral 
contraceptive pills or estrogen replacement therapy increases the risk of 
hyperplasia and cancer, combination oral contraceptive pills and 
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combination hormone replacement therapy does not increase and may 
decrease the risk of hyperplasia and cancer.(20) 
The most common clinical presentation of patients with endometrial 
hyperplasia is abnormal uterine bleeding, whether in the form of 
menorrhagia, metrorrhagia, or postmenopausal bleeding. Others present 
with abnormal vaginal discharge or Pap smear results showing glandular 
abnormalities. 
Diagnosis of endometrial hyperplasia is usually made by sampling 
the endometrial cavity. Tissue sampling should be performed in women 
with risk factors who present with symptoms of abnormal vaginal bleeding 
or discharge. This includes women older than 40 years with abnormal 
bleeding, younger than 40 years with bleeding and risk factors, with 
persistent bleeding, and with unopposed estrogen replacement therapy. In 
addition, a biopsy should be performed in women with AGUS (atypical 
glandular cells of undetermined significance) Pap smear or endometrial 
cells in Pap smears of women older than 40 years.(27) While no evidence of 
improved survival has been documented, some also advocate routine 
screening by endometrial biopsy in asymptomatic women with hereditary 
nonpolyposis colorectal cancer (HNPCC) syndrome or those on tamoxifen 
therapy. 
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Treatment: 
Once a tissue diagnosis of endometrial hyperplasia is made, 
treatment depends on the patient's symptoms such as the degree of 
bleeding, presence of cytologic atypia and patient's surgical risks. 
Progestins can effectively treat endometrial hyperplasia, and they can serve 
as preventiors of recurrence in those with continued risk factors. 
Hyperplasia without atypia responds well to progestins. More than 98% of 
women with hyperplasia treated with cyclic progestins experienced 
regression of the disease in 3-6 months. The PEPI trial showed a 94% 
normalization of complex or atypical hyperplasia in 45 women treated with 
progestins.Multiple regimens of progestin therapy have been found 
effective in reversing hyperplasia.(28) 
If hyperplasia with atypia is found on dilatation and curettag) or 
endometrial biopsy, definitive treatment with hysterectomy is 
recommended due to the high rate of concurrent endometrial cancer. 
However, if the patient is not a surgical candidate, then concurrent cancer 
must first be ruled out by D & C with hysteroscopy prior to medical 
management. . Biopsy is recommended after 3 months to check for 
response to medical therapy, and continued surveillance after regression of 
the lesion is recommended every 6-12 months if risk factors persist.(29)  
 Endometrial adenocarcinoma: is the most common malignant 
tumor of the female genital tract. This neoplasm represents a biologically 
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and morphologically diverse tumor with different pathogenesis.(30) The 
typical endometrial adenocarcinoma is well to moderately differentiated 
with or without squamous differentiation and accounts for 80-85% of all 
endometrial adenocarinoma.The typical patient is perimenopausal or 
postmenopausal obese ,hypertensive and diabetic. The low grade tumors 
are frequently associated with atypical hyperplasias that result from 
unopposed estrogenic stimulation. The prognosis is generally good, with a 
5 years survival of 80% or better.The high grade carcinoma appears to be 
less related to sustained estrogen stimulation.(30) These tumors account 
for10-15% of all endometrial carcinomas and include histologic subtypes 
such as clear and serous carcinomas along with other carcinomas that show 
high grade nuclear features. The tumors tend to occur in older post 
menopausal women. They usually invade the myometrium deeply, 
permeate lymphatic and vascular channels, and may show extrauterine 
spread at the time of hysterectomy.(12)  
Age: 
Endometrial adenocarcinoma occurs during the reproductive and 
menopausal years. The median age of women with this malignancy is early 
in the seventh decade of life, although most patients are aged 50-59 years. 
Approximately 5% of women younger than 40 years have adenocarcinoma, 
and 20-25% of women are diagnosed before menopause.(12)  
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Causes: 
Multiple epidemiological risk factors have been identified in patients 
who have adenocarcinoma of the endometrium.  
a. Endogenous factors: Nulliparity also increases risk 2- to 3-fold 
compared with parity. An individual who has had a late menopause 
(aged >52 y) also appears to have an increased risk. 
b. Unopposed estrogen: Unopposed estrogen, either as replacement 
therapy or endogenously produced (e.g., granulosa cell tumor, 
polycystic ovarian disease), increases the risk of endometrial cancer 
several times. 
c. Obesity is known to increase endogenous estrogen because the presence 
of fat appears to be responsible for the conversion of androstenedione to 
estrogen compounds at a much higher rate than if fat is not present. 
Anovulation which may be secondary to unopposed estrogen also 
appears to contribute to this situation.(31) 
Tamoxifen The most widely used anticancer drug is tamoxifen, and 
this drug has been suggested by some studies to cause an increased 
incidence of adenocarcinoma of the endometrium. These data were derived 
from retrospective analyses in which adenocarcinoma of the endometrium 
was not an end point in multiple prospective randomized studies evaluating 
the role of tamoxifen in patients with breast cancer. In contrast to 
tamoxifen, increasing data indicate that the use of combination oral 
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contraceptives (OCs) decreases the risk of developing endometrial cancer 
(32). Several studies have noted that women who use OCs at some time 
have a 0.5 relative risk of developing endometrial cancer compared with 
women who have never used OCs. 
Associated medical conditions:  
Some associated medical conditions have been found to increase the 
incidence of endometrial cancer. 
Breast, ovarian.and colon .cancers are frequently observed in women 
with endometrial cancer. Data suggest that women who have had breast 
cancer have a 2- to 3-fold increased risk of subsequently developing 
endometrial cancer. Women who have hereditary nonpolyposis colon 
cancer (HNPCC) appear to have a markedly increased risk for developing 
endometrial cancer. Women with HNPCC account for only 2-10% of all 
female cases of colon cancer, but approximately 5% of all endometrial 
cancers occur in women with this risk factor. These women have a 22-50% 
lifetime risk of developing endometrial cancer, and the disease tends to 
occur at a younger age (approximately 15 years earlier). The greatest risk 
of developing endometrial cancer in women with HNPCC occurs from age 
40-60 years, at which time the absolute risk is greater than 1% per year. 
f. Family history:  
Individuals with a family history of endometrial cancer appear to be 
at increased risk.(32)   
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Pathogenesis of endometrial adenocarcinoma: 
Endometrial adenocarcinomas that are associated with hyperplasia 
and the aforementioned risk factors tend either to be well differentiated 
mimicking normal endometrial glands (endometrioid) in histologic 
appearance,or to display altered differentiation (mucinous,tubal,squmaous 
differentiation).  This group of tumours is associated with a more 
favourable prognosis than tumours without hyperplasia .Although 
endometrial carcinomas may be associated with separate primary neoplasm 
arising in ovarian endometriosis; they tend not to spread to peritoneal 
surface.(30) 
Endometrioid adenocarcinoma is closely linked to prolonged 
estrogenic stimulation of the endometrium.In addition to treatment with 
exogenous oestrogen, obesity diabetes, nullparity, early menarche and late 
menopause. Each risk factor points to relative hyperestrinisim, Women 
with ovarian a genesis do not develop endometrial cancer unless treated 
with exogenous oestrogen   
Nonendometrioid cancer especially serous and clear cell 
adenocarcinoma,are unrelated to oestrogen exposure and usually occurs in 
women in their 60s and 70s . The adjacent endometrium is usually atrophic, 
a sign of oestrogen deficiency. 
Occasionally, the tumour may show a precursor form, term 
endometrial intraepithelial neaplasia. 
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Endometrial cancer also occurs in association with a higher 
incidence of both breast and ovarian cancer in closely related women 
suggesting a genetic predisposition.Moreover, it is the most common extra 
colonic cancer in women with the hereditary nonpolyposis syndrome 
(Lynsch syndromeII), which is also associated with breast and ovarian 
cancers.(34) 
WHO classification of endometrial adenocarcinoma:(35)   
- Endometrioid adenocarcinoma (NOS) 
- Variants: 
Ciliated 
secretory 
- Adenocarcinoma, NOS, with squamous differentiation. 
- Mucinous adenocarcinoma. 
- Secretary adenocarcinoma. 
- Clear adenocarcinoma. 
- Squamous adenocarcinma. 
- Undifferentiated carcinoma. 
- Mixed carcinoma. 
- Metastatic carcinoma. 
Endometrioid adenocarcinoma (NOS): 
This type of endometrial cancer is composed entirely of glandular 
cells and it is the most common histologic variants. Many examples of 
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endometrial adenocarcinoma have the typical, usual or (not other wise 
specified) pattern referred to as endometrioid carcinoma. More than one 
half of all endometrial carcinomas have this typical endometrioid pattern 
from 20-30% of endometrial carcinomas shown an endometrioid pattern 
with squamous differentiation. Previously these tumours with squamous 
differentiation were separated into two categories: adenoacanthoma 
denoted tumour that had a cytologically benign-appearing squamous 
epithelium (squamous metaplasia), and adenosquamous carcinoma denoted 
tumour that had a cytologically malignant appearing component. More 
recently, studies have shown that endometrioid carcinomas with or without 
squamous differentiation behave in the same fashion when stratified 
according to the grade of the glandular components .Accordingly, these 
tumours are best classified as adenocarcinomas with squamous 
differentiation and graded. The terms adenoacanthoma and adenosquamous 
carcinoma are no longer used for endometrial carcinomas.(12)  
Serous adenocarcinoma: 
Histologically resembles serous adenocarcinoma of the ovary. It also 
behaves more like ovarian carcinomas than endometrial tumours, often 
showing transcoelomic spread (34).This tumour arises within atrophic 
endometrium from a precursor known as endometrial intraepithelial 
carcinoma (EIC).(33)  
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Clear cell adenocarcinoma: 
It is a tumour of elderly women, It is composed of large cells with 
copious cytoplasmic glycogen (clear cell) or of cells with bulbous nuclei 
that line glandular lumina (hobnail cells). Clear cell and serous carcinoma 
are poorly differentiated adenocarcioma with poor prognosis. 
Secretory carcinoma: 
Describes cells with subnuclear vacuolization, usually in 
premenopausal women, the tumour is well differentiated. Secretory 
carcinoma has the most favourable outcome of any adenocarcinoma, 
presumably because the cells are well differentiated. 
Grading of endometrial carcinoma: 
Grade1: well differentiated adenocarcinoma (95% of the tumour 
forms glands. 
Grade 2: differentiated carcinoma with partly solid areas (<50%). 
Grade 3: predominantly solid or entirely undifferentiated (>50% of 
the tumour has a solid growth pattern). 
Serous and clear cell carcinoma is grade 3 tumour. 
International Federation of Gynaecology and Obstetrics (FIGO) 
staging of corpus cancer:  
Stage            Description 
Ia G123:        Tumour limited to the endometrium 
I b G123     Invasion of less than half of the myometrium 
 26
IcG123     Invasion of more than half of the myometruim 
IIaG123     Endocervical glandular involvement only 
IIb G123   Cervical stromal invasion 
IIIaG123  Tumour invades serosa and or adnexae and or positive 
peritoneal cytology 
IIIb G123   Vaginal metastases 
IIIc G123  Metastases to pelvic and or paraaortic lymph nodes 
IVa G123  Tumour invasion of bladder and or bowel mucosa 
IVb      Distant metastases including intraabdominal and or 
inguinal lymph nodes 
Staging of endometrial cancer employed a variety of histologic risk 
factors including grade, depth of myometrial invasion, involvement of the 
cervix and peritoneal cytology.(35) 
Management: 
Women with well differentiated cancer confined to the endometrium 
are usually treated by simple hysterectomy alone or in combination with 
radiation giving about90% 5years survival in stageI(grade 1 or2)disease. 
This rate drops to75% for grade 3stage I disease and to 50% or less for 
stage II and III endometrial carcinoma.(30) Postoperative radiation is 
administered if (1) the tumour is poorly differentiated (2) the myometrium 
is more than superficially involved. (3) The cervix is involved (4) the 
lymph nodes contain metastases.(34)  
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Prognosis: 
Survival in endometrial carcinoma is related to multiple factors 
including (1) the stage and histologic grade and type, (2) age,                         
(3) progesterone receptor activity, (4) depth of myometrial invasion,               
(5) other measurable risk factors such as extent of lymphovascular invasion 
and results of peritoneal washings. The actual survival rate of all patients 
with endometrial carcinoma following treatment is 80% after the second 
year decreasing to65% after 10 years.(34)  
Uterine papillary serous and clear cell carcinoma have propensity for 
extrauterine (lymphatic or transtubal) spread, even when confined to the 
endometrium or its surface epithelium <50% of patients with these tumours 
are alive 3 years after diagnosis and 35% after 5 years.(30)  
Endometrial polyps: 
Definition: 
A polyp is a benign overgrowth in the endometrial cavity. Polyps 
occur over a wide age range but is most common in the fourth and fifth 
decades, becoming less frequent after the age of 60.(12) 
Pathogenesis: 
Polyps are thought to arise from endometrial foci that are 
hypersensitive to estrogenic stimulation or unresponsive to progesterone. In 
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either case, such foci don’t slough during menstruation and continue to 
grow.(34) 
Pathology: 
Most endometrial polyps arise in the fundus, although they may 
originate in any location within the endometrial cavity. They vary from 
several millimetres in length to a growth filling the entire endometrial 
cavity, most are solitary, but 20% are multiple.(34) 
Classification and histologic features: 
Classification of endometrial polyps: 
- Hyperplastic. 
- Atrophic. 
- Functional. 
- Adenomymatous. 
- Mixed endometrial-endocervical. 
- A typical polypoid adenomyoma. 
This classification has little clinical significance but is useful for 
correct identification of these lesions and separating them from 
hyperplasia.(12) 
Despite their diverse growth patterns, all polyps show several 
histologic features that facilitate their diagnosis. One important feature of 
polyps is the presence of large, polypoid tissue fragments, these fragments 
tend to be lined on three sides by surface epithelium. Often much smaller 
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fragments of normal endometrium are admixed with the large fragments of 
a polyp. 
Polyps commonly show dense stroma. In addition they frequently 
contain thick walled blood vessels especially when they become large. 
Small veins in the superficial stroma become ectatic. The glands in polyps 
are irregular in shape and have a highly variable architecture. In addition to 
these characteristic features, a polyp may show evidence of focal glandular 
and stromal break down, usually due to thrombosis of superficial dilated 
veins.(37)   
Hyperplastic polyps: Are most common, they are highly variable in 
size up to several centimetres in great dimension. Regardless of size, they 
show irregular proliferating glands with pseudo stratified nuclei and mitotic 
activity. The surface and glandular epithelium often show epithelial 
cytoplasmic changes. These include squamous, eosinophilic and ciliated 
cell changes. 
Atrophic polyps: Also known as inactive polyps are usually seen in 
postmenopausal women. These polyps contain atrophic glands lined by low 
columnar epithelium showing no mitotic activity. The stroma appears 
dense and fibrotic. 
Functional polyps: These polyps like the endometrium around them 
are hormonally responsive and show proliferative or secretory changes. 
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The stroma may show oedema or predecidual change but often is dense and 
in- active. 
Mixed endometrial-endocervical polyps: Some polyps originate in 
the upper endocervix and lower uterine segment and show both 
endocervical and endometrial type of glands. These polyps tend to have a 
fibrous stroma resembling the stroma of the lower uterine segment. 
Adenomymatous polyps: these polyps have smooth muscle in their 
stroma usually as irregular bundles and strands in proximity to thick walled 
vessels. Most often these are large polyps in which the stroma has 
undergone partial smooth muscle proliferation.(38,39)  
Atypical polypoid adenomyoma:  This is an unusual and distinctive 
polyp characterized by glands that are lined by a typical epithelium and 
surrounded by cellular smooth muscle.(40) It typically occurs in 
premenopausal or perimenopausal women with mean age of 40 years. A 
few cases have been associated with Turner syndrome and appear to be a 
complication of long term stimulation of the endometrium.(41) 
Endometritis: Is usually a disorder of reproductive years although it 
may occur in postmenopausal patients. Endometrial inflammation typically 
accompanies PID of the upper genital tract. It may also be associated with a 
recent pregnancy either an abortion or term pregnancy. Other possible 
causes include instrumentation, such as prior biopsy or the presence of an 
organic lesion such as polyp, leiomyoma, hyperplasia or carcinoma. 
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Endometrial inflammation often is non specific and rarely has 
morphologic features that indicate a definite aetiology. 
The non specific forms of endometritis have traditionally been 
separated in to acute and chronic forms depending on the type of 
inflammatory infiltrate, most are referred to as chronic non specific 
endometritis. 
Acute endometrial inflammation is relatively infrequent except for 
puerperal related infection.(12)  
Nonspecific endometritis: endometritis may be focal or diffuse and 
can range from a subtle inflammatory infiltrate to a pronounced 
inflammatory reaction, endometritis typically shows patterns of mixed 
inflammatory infiltrate containing plasma cells and lymphocytes and not 
infrequently neutrophils and eosinophils. The other morphologic changes 
include reactive stroma, epithelial changes, abnormal glandular 
development and evidence of glandular and stromal break down.(42)  
Causes of chronic endometritis: 
1. Granulomatous endometritis: 
Granulomatous inflammation of the endometrium is in frequent, and 
often the process is due to mycobacterium tuberculosis, and infection 
usually indicates advance disease. 
Tuberculous endometritis causes abnormal uterine bleeding in 
postmenopausal patients.(43) 
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2. Actinomycosis: 
Infection by A. israeli is another rare cause of endometritis.The 
organism typically is found in endometritis associated with the use of 
intrauterine cervical device .The organisms show the typical sulphur 
granules morphology and can be stained by tissue gram stain (methen 
amine silver stain).(44)   
3. Cytomegalovirus: 
This occurs in immunosuppressed patients or it may be found in 
women with no known underlying disorders, regardless of the 
immunologic status. The issue shows the characteristic nuclear and 
cytoplasmic inclusions in the epithelial cells and occasional endothelial 
cells.(12)  
4. Herpes virus: 
Rarely infects the endometrium, but it may occur, usually as an 
ascending process associated with cervical infection. When present in the 
endometrium it can cause patchy necrosis of the glands and stroma .the 
diagnosis is established by identifying cells that show typical cytopathic 
effect. Type A inclusion and multinucleated cells with molded ground glass 
nuclei can be found in the glandular epithelium or the stroma in areas of 
necrosis.(12) 
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5. Chlamydia.trachomatis: 
Infection is usually marked. The inflammatory infiltrate tends to be 
diffuse with plasma cells, lymphocytes, and lymphoid follicles with typical 
lymphocytes. The inflammatory response to Chlamydia also may be mixed 
with an infiltrate of acute as well as chronic inflammatory cells.Stromal 
necrosis and reactive atypia of the epithelium may be present.(45) 
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JUSTIFICATION 
 
PMB is a common clinical problem in both general and hospital 
settings, representing 5% of all gynaecologic outpatients attendances. The 
incidence of spontaneously occurring PMB in the general population can 
be as high as 10% immediately after menopause. 
PMB is the commonest symptom of carcinoma of the endometrium. 
Of postmenopausal women with vaginal bleeding, 10%-15% have 
endometrial carcinoma. Endometrial cancer is the most common 
malignancy of the female genital tract accounting for 7% of all invasive 
cancer of women excluding skin cancer. Unlike other malignancies, 
endometrial cancer often presents at an early stage when there is a 
possibility of curative treatment by hysterectomy. Survival decreases with 
increase staging and lower histological differentiation. Thus patients 
presenting with PMB should be worked up on priority basis to detect and 
mange carcinoma at an early stage. 
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OBJECTIVES  
 
General objective: 
To identify the histopathological patterns of postmenopausal 
bleeding in endometrial biopsies received in the National Health 
Laboratory in Khartoum in the years2009-June 2010 
 
Specific objectives: 
1. To identify the frequency and distribution of histopathological 
patterns of endometrial biopsies taken from women presenting with 
postmenopausal bleeding. 
2. To estimate the risk of endometrial cancer in endometrial biopsies 
taken from women presenting with postmenopausal bleeding. 
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MATERIALS AND METHODS  
 
Study design:  
Retrospective (cross-sectional), descriptive study. 
Study field:  
Histopathology department/National health laboratory. 
Study population:  
The study included 146 tissue specimens taken from women 
presenting with postmenopausal bleeding.  
Inclusion criteria: 
All endometrial biopsies taken from women presenting with 
postmenopausal bleeding. 
Exclusion criteria: 
1. Failure to find paraffin block and or slides. 
2. Endometrial biopsies taken from women presenting with vaginal 
bleeding during reproductive age. 
Specimen collection and identification: 
All issued reports from National health laboratory during the period 
from January 2009-june2010 were revised to obtain the lab numbers of all 
cases presented with postmenopausal bleeding. Tissue blocks and slides 
were collected, accordingly, slides were revised. 
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Materials and methods of identification: 
Endometrial biopsies or hysterectomy specimens were fixed in 
formalin. Representative pieces of tissue were selected by a pathologist, 
processed by an automatic tissue processor, and then embedded in paraffin 
wax in form of blocks. 
 Sections average 4 micrones in thickness were cut in a rotary 
microtome. Slides were prepared and stained with heamatoxylin and eosin 
(H&E). 
For the purpose of this study slides were prepared from retrieved 
blocks and sections reexamined. The data were analyzed using computer 
program SPSS. 
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RESULTS 
The age of women presenting with PMB in whom endometrial 
sampling was performed ranged from (45-90) years, with the highest 
frequency in (45-54) age group 59(40.4%) as shown in (Table 1). 
Ninety five (65.06%) of endometrial biopsies were obtained by 
dilatation and curettage, 46(31.50%) by hysterectomy and 5(3.44%) by 
polypectomy (Figure 1). 
Histopathological patterns of endometrial biopsies: 
The majority of the lesions were benign 71.9% while malignant 
conditions constituted only (15.8%) as shown in (Figure 2). 
Endometrial polyps were the predominant histologic pattern 
constituted 19.9%, 62.1% were hyperplastic, 27.6% were atrophic, 
functional polyps seen in 6.9% of biopsies, 3.4% were adenomyomatous 
(Tables 2 and 3). 
Metaplastic change was diagnosed in38.9% of hyperplastic polyps, 
57.1% displayed squamous metaplastic change, syncytial papillary change 
in 14.3% and ciliated metaplasia in 28.6% (Table 4, Figure 4). 
Endometrial hyperplasia without atypia was diagnosed in 17.8% of 
biopsies, 84.62% were simple hyperplasia and 15.38% were complex 
hyperplasia (Figure 3).  
Endometrial cancer constituted 15.8%, endometrial adenocarcinoma 
was the predominant endometrial cancer with a figure of (73.9%), 
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squamous carcinoma came second (17.4%), stromal sarcoma and serous 
cell carcinoma were both rare, constituting 4.3% for each. Most 
endometrial adenocarcinoma (41.2%) were poorly differentiated, well 
differentiated adenocarcinoma in 23.5% and 35.3% were moderately 
differentiated adenocarcinoma (Tables 5 and 6). 
Proliferative endometrium was diagnosed in 11% of endometrial 
biopsies, atrophic endometrium in 7.5% and in active endometrium in 1.4% 
(Table 2). 
Other patterns including hormonal effects, secretory endometrium 
and nondatable endometrium were diagnosed in 10% of biopsies, while, 
12.3% of biopsies were inadequate for interpretation (Figure 2).   
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Table (1) Age distribution among the study population 
 
Age (in years) Frequency Percentage 
45-54 59 40.4 
55-64 47 32.2 
65-74 30 20.5 
75-84 7 4.8 
85-94 3 2.1 
Total 146 100.0 
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Table (2) Distribution of histopathological patterns of  
the study population 
Patterns Frequency Percentage 
Proliferative endometrium 16 11.0 
Inactive endometrium 2 1.4 
Atrophic endometrium 11 7.5 
Edometrial hyperplasia without atypia 26 17.8 
Endometrial polyps 29 19.9 
Malignancy 23 15.8 
Chronic endometritis 7 4.8 
Inadequate for interpretation 18 12.3 
Prolifreative endometrium+hyperplastic polyps 2 1.4 
Complex hyperplasia without atypia + 
hyperplastic polyp with ciliated change. 
 
1 
 
0.7 
Simple hyperplasia+adenomyomatous polyps 1 0.7 
Others 10 6.8 
Total 146 100.0 
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Table (3) Histolgic subtypes of endometrial polyps 
Type Frequency Percentage  
Hyperplastic 18 62.1 
Atrophic 8 27.6 
Functional 2 6.9 
Adenomyomatous 1 3.4 
Total 29 100.0 
 
 
 
 
Table (4) Distribution of metaplastic change in hyperplastic polyps 
 Metaplastic change Frequency Percentage 
Yes 7 38.9 
No   11 61.1 
Total 18 100.0 
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Table (5) Histologic subtypes of endometrial cancer 
 Type Frequency Percentage 
Adenocarcinoma 17 73.9 
Squamous cell carcinoma 4 17.4 
Stormal sarcoma 1 4.3 
Serous carcinoma 1 4.3 
Total 23 100.0 
 
 
 
 
Table (6) Degree of differentiation of endometrial adenocarcinoma 
 Degree of differentiation Frequency Percentage 
Well differentiated (grade I) 4 23.5 
Moderate differentiated  (grade II) 6 35.3 
Poor differentiated  (grade III) 7 41.2 
Total 17 100.0 
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Figure (3) Types of endometrial hyperplasia (n = 26) 
COMPLEX, 15.38%
SIMPLE, 84.62%
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Figure (4) Distribution of metaplastic change in 
 hyperplastic polyps  (n = 7) 
 
57.14%
28.57%
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40.00%
50.00%
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Figure (5) Simple Hyperplasia 
 
 
Simple hyperplasia(cystic hyperplasia) glands are cystically dilated 
with occasional outpouching surrounded by abundant densely cellular 
stroma and give a (Swiss cheese appearance) .No cellular a typia is 
present(H&E,X10 objective). 
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Figure (6) Endometrial adenocarcinoma (endometrioid type) 
 
Endometrial adenocarcinoma (endometrioid type,well differentiated) 
(H & E, 40x objective) 
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Figure (7) Endometrial adenocarcinoma showing myometrial invasion 
 
 
Endometrial adenocarcinoma showing myometrial invasion (H & E 
10x objective). 
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DISCUSSION 
 
PMB is a common problem in both hospital and general settings. 
Representing 5 % of all gynaecologic outpatients attendance. Patients with 
postmenopausal bleeding have 10-15% chance to develop endometrial 
carcinoma. 
This study is a retrospective crossectional study designated to 
describe histopathological patterns of PMB in endometrial biopsies. It was 
carried out in the period 2009-june2010 and included 146 endometrial 
biopsies taken from women presenting with PMB. 12.3% of biopsies were 
in adequate for interpretation. 
The majority of histopathological patterns were benign 
lesions(84%),much higher than the reported incidence in developed 
countries where benign pathology was found to be >60 %,and of Pamela et 
al from India with a  prevalence of 63.6%.This may be attributed to the 
contribution of other benign lesions in this study not included in previous 
studies e.g. chronic endometritis.  
In this study endometrial polyps were the predominant histologic 
finding with a figure of 19.9%. That is higher than that reported by   
Kauser, Jillani, Razia Bhadour, Kharo et al  incidence of 12%(46),with 
hypperplastic polyps being  the most frequent type. The malignancy risk of 
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endometrial polyps in post menopausal women was correlated to the 
presence or absence of abnormal uterine bleeding.(47)  
Armando et al., concluded that premalignant lesions were associated 
with age and PMB.(48)Endometrial hyperplasia with or without atypia is 
considered to be a precursor of endometrial carcinoma, and concurrent 
carcinoma at rates ranging 17-52%(21). In this study incidence of 
endometrial hyperplasia was found to be 17.8% that is comparable to 
reported incidence of 14.3% in a study by Veena, et al that included 108 
cases with PMB.(49) 
The most recent prevalence of endometrial cancer is quoted to be 
around9.9-11% .in the present study, endometrial carcinoma accounts 
for15.8%  which is higher than the reported incidence of Youssef et al.,(50)  
with endometrioid adenocarcinoma being the most  frequent type  
(73.9/%).  Papillary serous carcinoma constituted 4.3%of endometrial 
cancer, which is almost consistent with the incidence written in the 
literature of 5-10%. The incidence of atrophic endometrium in this study 
was found to be 7.5%. This can easily be explained on the background of 
physiological change during menopause.(1) 
The exact cause of bleeding from atrophic endometrium isn’t known. 
It is postulated to be due to anatomic vascular variation or local abnormal 
haemostatic mechanism.(51) In the present study, proliferative endometrium 
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accounts for 11%, that’s higher as compared to the reported incidence of 
Veena, et al., was 8.6%. 
Proliferative endomtrium may be due to fluctuating levels of 
progesterone from follicular remnants, the effects persist up to 15years 
after cessation of menses.(52) 
Although chronic endometritis is a disorder of re productive years,it 
was diagnosed in 4.5% of biopsies. 
Chronic endometritis in postmenopausal years maybe attributed to 
endometrial inflammation following instrumentation such as prior biopsy 
or organic lesions such as hyperplasia, polyp or carcinoma.(12)   
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CONCLUSION 
 
• The majority of histopathological findings in PMB were benign lesions 
(71.9%), among benign lesions; endometrial polyps were the most 
frequent pattern.  
• There was a high incidence of endometrial hyperplasia (17.8%), however, 
all were non atypical hyperplasia. 
• The malignancy risk of endometrial cancer was found to be 15.8%. 
• Endometrial adenocarcinoma was the commonest endometrial cancer 
(73.9%), 41.4% were poorly differentiated adenocarcinoma.   
• This study showed a high prevalence of endometrial biopsies inadequate 
for interpretation (12.3%). 
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RECOMMENDATIONS 
 
• PMB is a serious problem not to be underestimated. 
• More prospective large scale studies are recommended to shed light on 
histopathological findings in PMB. 
• Medical treatment and regular follow up by endometrial sampling is 
recommended for all cases of endometrial hyperplasia, in order to detect 
and diagnose endometrial cancer at an early stage. 
• Provision of guidelines and protocol for endometrial sampling as the 
definite diagnosis and staging of endometrial cancer rely on 
histopathological examination. 
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Questionnaire 
Histopathological patterns of endometrial biopsies in patients with 
postmenopausal bleeding (histopathological study) 
  
 Date: ……………………                           lab number: …………………… 
Clinical data: 
Age: …………………………………………………………..                            
 Clinical presentation: ………………………………………….. 
Procedure of endometrial sampling: ……………………………………………………….. 
Dilatation and curettage (D&C)  
Hysterectomy …………………… 
Polypectomy …………………… 
Histological findings: 
Microscopy: …………………… 
Histological type …………………… 
Grading of endometrial adenocarcinoma: 
Well  …………………………………………………………….  
Moderate ………………………………………………………          
Poor differentiated: ……………………………………. 
 
 
 
 
 
 
 
 
 
 
 64
 
 
 
 
 
 
